These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 26033112)

  • 21. Risk factors for poor oocyte yield and oocyte immaturity after GnRH agonist triggering.
    Gambini S; Sonigo C; Robin G; Cedrin-Durnerin I; Vinolas C; Sifer C; Boumerdassi Y; Mayeur A; Gallot V; Grynberg M; Peigné M
    Hum Reprod; 2024 May; 39(5):963-973. PubMed ID: 38452353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction-intrauterine insemination to in vitro fertilization conversions, independent of age and estradiol level on the day of human chorionic gonadotropin administration.
    Quaas AM; Missmer SA; Ginsburg ES
    Fertil Steril; 2010 Feb; 93(2):605-8. PubMed ID: 19324340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration.
    Hugues JN; Massé-Laroche E; Reboul-Marty J; Boîko O; Meynant C; Cédrin-Durnerin I
    Fertil Steril; 2011 Sep; 96(3):600-4. PubMed ID: 21880277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study.
    Nyachieo A; Spiessens C; Chai DC; Mwenda JM; D'Hooghe TM
    Fertil Steril; 2009 Feb; 91(2):602-10. PubMed ID: 18328482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
    Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
    Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
    Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation.
    Geng Y; Xun Y; Hu S; Lai Q; Jin L
    Gynecol Endocrinol; 2019 Apr; 35(4):309-313. PubMed ID: 30430883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there a preferred time interval between gonadotropin-releasing hormone (GnRH) agonist trigger and oocyte retrieval in GnRH antagonist cycles? A retrospective cohort of planned fertility preservation cycles.
    Ranit H; Shmuel H; Ahlad A; Shirley G; Meny H; Tal I; Assaf BM; Chana AL; Yaakov B; Efrat EB; Anat HK
    J Assist Reprod Genet; 2024 Jun; 41(6):1531-1538. PubMed ID: 38492156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of dual trigger with combination GnRH agonist and hCG versus hCG alone trigger of oocyte maturation for normal ovarian responders.
    Zhou X; Guo P; Chen X; Ye D; Liu Y; Chen S
    Int J Gynaecol Obstet; 2018 Jun; 141(3):327-331. PubMed ID: 29388691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study.
    Huang P; Tang M; Qin A
    J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):99-102. PubMed ID: 30321608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ultrashort gonadotropin-releasing hormone agonist combined with flexible multidose gonadotropin-releasing hormone antagonist for poor responders in in vitro fertilization/embryo transfer programs.
    Orvieto R; Kruchkovich J; Rabinson J; Zohav E; Anteby EY; Meltcer S
    Fertil Steril; 2008 Jul; 90(1):228-30. PubMed ID: 17681292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How far is too far? Does time interval between GnRH antagonist and GnRH agonist trigger in GnRH antagonist cycles matter?
    Hershko Klement A; Orvieto R; Esh Broder E; Frei J; Solnica A; Zandman O; Holzer H; Haas J
    Reprod Biomed Online; 2021 Aug; 43(2):233-238. PubMed ID: 34215488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
    Chen SL; Ye DS; Chen X; Yang XH; Zheng HY; Tang Y; He YX; Guo W
    Hum Reprod; 2012 May; 27(5):1351-6. PubMed ID: 22419746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J; Ben-Haroush A; Lande Y; Sapir O; Pinkas H; Fisch B
    Fertil Steril; 2009 Feb; 91(2):377-82. PubMed ID: 18321490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles.
    Lai Q; Zhang H; Zhu G; Li Y; Jin L; He L; Zhang Z; Yang P; Yu Q; Zhang S; Xu JF; Wang CY
    Int J Clin Exp Pathol; 2013; 6(9):1903-10. PubMed ID: 24040457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
    Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
    Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum estradiol level change after human chorionic gonadotropin administration had no correlation with live birth rate in IVF cycles.
    Huang R; Fang C; Wang N; Li L; Yi Y; Liang X
    Eur J Obstet Gynecol Reprod Biol; 2014 Jul; 178():177-82. PubMed ID: 24862918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.